Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors
Gregory W. Schwartz(University Health Network), Robert B. Faryabi(Cancer Research Institute), Martin Carroll(University of Pennsylvania), Ashkan Bigdeli(UPMC Hillman Cancer Center), Alexander E. Perl(University of Pennsylvania), Rachel Astles(University of Pennsylvania), Anne W. Lehman(University of Pennsylvania), Priya Velu(University of Pennsylvania), Yeqiao Zhou(Cancer Research Institute), Bryan Manning(The Wistar Institute), Mingyao Li(California University of Pennsylvania), Jennifer J.D. Morrissette(University of Pennsylvania)
Cited by 12
Related Papers
(untitled)
|Edinburgh Research Explorer (University of Edinburgh)|0|2.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Single-cell transcriptomics of the mouse kidney reveals potential cellular targets of kidney disease
|Science|2018|1.2k
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
|Nature|2012|745
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508